摘要
Abstract
Objective To explore the intrinsic links between FDG uptake in neoadjuvant chemotherapy and molecular biological markers of breast cancer. Methods In this study, 211 patients with newly-diagnosed breast cancer completed 18F-FDG PET-CT before neoadjuvant chemotherapy, 49 cases completed PET-CT after the first course of neoadjuvant chemotherapy, 49 cases cases completed PET-CT after the second course of neoadjuvant chemotherapy. SUVmax was measured everytime and the rate of change was calculated. Before neoadjuvant chemotherapy, breast cancer tissues were taken for ER, PR, HER -2, Ki -67 and p53 immumohistochemical examination. The correlations of SUVmax, ⊿SUVmax 1% and ⊿SUVmax 2% with the expressions of ER, PR, HER-2, Ki-67 and p53 in breast cancer were analyzed. Results SUVmax in the ER-negative group was significantly higher than that in the ER-positive group ( < 0.05). SUVmax in the PR-negative group was significantly higher than that in the PR-positive group ( <0.05). ⊿SUVmax 2% in the PR-negative group was higher than that in the PR-positive group ( <0.05). SUVmax and ⊿SUVmax 2% in the Ki-67-positive group were higher than those in the Ki-67-negative group ( < 0.05). Conclusions FDG metabolism in ER and PR negative patients is higher than that in ER and PR positive patients. ⊿SUVmax 2% in PR negative patients is higher than that in PR positive patients, suggesting that PR negative patients are more sensitive to neoadjuvant chemotherapy. SUVmax of Ki-67 positive patients is higher than that of Ki-67 negative patietns, suggesting FDG metabolism may reflect the proliferative degree of breat cancer. Ki-67 positive patients have a higher ⊿SUVmax 2%, which means Ki-67 positive patients are more sensitive to neoadjuvant chemotherapy.关键词
18F-FDGPET-CT/雌激素受体/孕激素受体/表皮生长因子受体-2/Ki-67Key words
18F-FDG PET-CT/estrogen receptor/progestogen receptor/human epidermal growth factor receptor-2/Ki-67分类
医药卫生
